Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by SundayMovieson Dec 13, 2022 10:07am
101 Views
Post# 35168231

RE:RE:All you can buy!!!

RE:RE:All you can buy!!!Davepark5

I need this baby to rocket up too. One thing at the time.
General market sentiment was very negative that is check off now.

Timing a rocket is difficult. Multiple possible launches... but so far so good. 
From now until Asco should be the window. I am going to be patient.

This remains the best opportunity for something going parabolic.
If not I still will make a decent return... 

Again GOBLET was just interim data (complete response). They got accelerated approval based on interim results.
Same for ADLAI interim data - but we can see 9.4 months of life as per september vs. 10.5 baseline

So very very promissing. I think the market is still not giving full credit to ONCY because both of these trial are interim data contrary to the other biotech that was mentionned here that got completed trial data.
<< Previous
Bullboard Posts
Next >>